SEC Tracker
Get the app

Marpai MRAI

Marpai FY 2024: revenue $28.2M, down 24%; diluted EPS −$1.92

Form
10-K
Filed
Period
Importance
Notable
Document
10-K

Key figures from this report

These are the numbers Marpai reported for the year ended Dec 31, 2024, as tagged in the filing’s XBRL data, each against the year before. A plain-English reading of this report is not written yet.

  1. Revenue$28.2M−24% from $37.2M in FY 202310-K income statement, on EDGAR
  2. Net income−$22.1MAgainst −$28.8M in FY 202310-K income statement, on EDGAR
  3. Diluted EPS−$1.92Against −$4.14 in FY 202310-K income statement, on EDGAR
  4. Cash and cash equivalents$764K−33% from $1.1M in FY 202310-K balance sheet, on EDGAR
  5. Cash from operations−$15.2MAgainst −$15.7M in FY 202310-K cash flow statement, on EDGAR

Every year in the financial tables

View on EDGAR

Open in the app

Get an email when Marpai files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 8090 and related industry codes: the same peer list as the financial tables.

  1. BioRestorative Therapies BRTX public float $11M, Jun 30, 2025
  2. Mangoceuticals MGRX public float $15M, Jun 30, 2025
  3. Elite Health Systems EHSI public float $24M, Jun 30, 2025
  4. Cryo Cell International CCEL public float $27M, May 31, 2025
  5. Pacific Health Care Organization PFHO public float $3M, Jun 30, 2025